Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8080551 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2023
(11 months ago) | |
US7390791 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Apr, 2025
(1 year, 18 days from now) | |
US7125879 | GILEAD SCIENCES INC | HIV inhibiting pyrimidines derivatives |
Apr, 2025
(1 year, 22 days from now) | |
US9296769 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
US8754065 | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Aug, 2032
(8 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7803788 | GILEAD SCIENCES INC | Prodrugs of phosphonate nucoleotide analogues |
Feb, 2022
(2 years ago) | |
US8101629 | GILEAD SCIENCES INC | Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile |
Aug, 2022
(1 year, 7 months ago) | |
US7390791 (Pediatric) | GILEAD SCIENCES INC | Prodrugs of phosphonate nucleotide analogues |
Oct, 2025
(1 year, 6 months from now) | |
US8754065 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) | |
US9296769 (Pediatric) | GILEAD SCIENCES INC | Tenofovir alafenamide hemifumarate |
Feb, 2033
(8 years from now) |
Odefsey is owned by Gilead Sciences Inc.
Odefsey contains Emtricitabine; Rilpivirine Hydrochloride; Tenofovir Alafenamide Fumarate.
Odefsey has a total of 10 drug patents out of which 3 drug patents have expired.
Expired drug patents of Odefsey are:
Odefsey was authorised for market use on 01 March, 2016.
Odefsey is available in tablet;oral dosage forms.
Odefsey can be used as treatment of hiv infection.
The generics of Odefsey are possible to be released after 15 February, 2033.
Market Authorisation Date: 01 March, 2016
Treatment: Treatment of hiv infection
Dosage: TABLET;ORAL